Foreward by Romano, Cesare P.R. et al.
Loyola of Los Angeles International 
and Comparative Law Review 
Volume 43 Number 3 Article 1 
2021 
Foreward 




Kerry Lynn Macintosh 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.lmu.edu/ilr 
 Part of the Health Law and Policy Commons, and the Science and Technology Law Commons 
Recommended Citation 
Cesare P.R. Romano, Jessica Almqvist, Andrea Boggio, Timo Faltus, Kerry Lynn Macintosh, and Scott J. 
Schweikart, Foreward, 43 Loy. L.A. Int'l & Comp. L. Rev. 183 (2021). 
Available at: https://digitalcommons.lmu.edu/ilr/vol43/iss3/1 
This Other is brought to you for free and open access by the Law Reviews at Digital Commons @ Loyola 
Marymount University and Loyola Law School. It has been accepted for inclusion in Loyola of Los Angeles 
International and Comparative Law Review by an authorized administrator of Digital Commons@Loyola Marymount 
University and Loyola Law School. For more information, please contact digitalcommons@lmu.edu. 
Foreward 
Authors 
Cesare P.R. Romano, Jessica Almqvist, Andrea Boggio, Timo Faltus, Kerry Lynn Macintosh, and Scott J. 
Schweikart 
This other is available in Loyola of Los Angeles International and Comparative Law Review: 
https://digitalcommons.lmu.edu/ilr/vol43/iss3/1 
ILR_TO_JCI (DO NOT DELETE) 5/12/21 1:52 PM 
 
183 
ILR Special Issue 
FOREWORD 
This special issue of the Loyola of Los Angeles International and 
Comparative Law Review brings together five essays on the national and 
international legal aspects of the modification of the genome of human 
germline cells (i.e. sperm and oocytes). They were written for a sympo-
sium scheduled for spring 2020, to be held at Loyola Law School, Los 
Angeles, to launch the book Human Germline Genome Modification and 
the Right to Science: A Comparative Study of National Laws and Policies 
(Boggio, Romano, & Almqvist eds., Cambridge University Press, 2019). 
As the COVID-19 pandemic started claiming victims by the thousands 
across the globe, the symposium was hastily called off, but publication of 
the symposium essays went ahead. The pandemic and the disconnected 
initial international response provided yet another stark reminder of the 
importance of international cooperation in the field of medicine and bio-
technology. 
Over the past twenty-five years, biotechnology has enormously ex-
panded the capacity to manipulate the building blocks of all life, includ-
ing humans. As early as 2000, Gregory Stock and John Campbell noted 
that the achievement of the capacity to make changes to human germline 
cells was “inevitable.”1 “The real question,” they postulated, was not 
“whether the technology will become feasible, but when and how it 
will.”2 The advent of the CRISPR/Cas9 family of genome editing tools 
during the second half of the 2010s answered the question of how. As to 
when, it was November 2018, when He Jianku, an associate professor in 
the Department of Biology of the Southern University of Science and 
Technology in Shenzhen, China, stunned the world by announcing that 
he had used CRISPR/Cas9 to edit the genome of at least two human em-
bryos. The world quickly condemned the rogue scientist, who was also 
sanctioned by the Chinese government, but what was done could not be 
undone and a new world had been ushered in, ready or not. 
 
 1. ENGINEERING THE HUMAN GERMLINE: AN EXPLORATION OF THE SCIENCE AND ETHICS 
OF ALTERING THE GENES WE PASS TO OUR CHILDREN 6 (Gregory Stock & John Campbell eds., 
2000). 
 2.  Id. at 5. 
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For legal and ethical reasons explained in depth in the book, 
germline gene therapies have not yet been legally clinically tested on hu-
mans, anywhere. However, basic research has made progress towards un-
locking CRISPR-based germline gene therapies to eliminate a long list of 
severe genetic disorders that claim or compromise the life of millions 
around the world. Whether these therapies will be able to move “from 
bench to bed,” to be clinically applied, depends on the regulatory frame-
works that each State, and all of them collectively, has in place, and those 
they will create in response to scientific, technological and legal chal-
lenges created by the application of CRISPR/Cas9 tools to the genome of 
human germline cells. 
The book analyzes how human germline genome modification is 
currently regulated in a selected, but fairly broad and representative, set 
of eighteen developed countries, and assesses these national governance 
practices in the light of the existing and emerging international legal ob-
ligations states have, including, of course, the obligation to respect inter-
national human rights. The five pieces in this symposium issue revisit 
some of the chapters in the book and add further material for discussion. 
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